M&A / Deals Biogen pens $1bn deal to buy immunology biotech RayThera PharmaphorumBiogen has agreed its second takeover deal of 2026, an acquisition of immunology start-up RayThera valued at up to $1 billion.Immunology & InflammationRead full story pharminent June 18, 2026 (Last updated: June 18, 2026) Pharmaphorum Biogen has agreed its second takeover deal of 2026, an acquisition of immunology start-up RayThera valued at up to $1 billion. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Previous PostNext: Heart drug biotech Kardigan raises $400m in upscaled IPO Related Stories M&A / Deals Heart drug biotech Kardigan raises $400m in upscaled IPO pharminent June 18, 2026 M&A / Deals Jazz orchestrates a $4bn cancer alliance with AbCellera pharminent June 17, 2026 M&A / Deals Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact pharminent June 17, 2026
